Andrew Eisen Selected Research

cimaglermin

1/2018	Transient Changes in Hepatic Physiology That Alter Bilirubin and Bile Acid Transport May Explain Elevations in Liver Chemistries Observed in Clinical Trials of GGF2 (Cimaglermin Alfa).
10/2017	Species-specific effects of neuregulin-1β (cimaglermin alfa) on glucose handling in animal models and humans with heart failure.
12/2016	A Phase I, Single Ascending Dose Study of Cimaglermin Alfa (Neuregulin 1β3) in Patients With Systolic Dysfunction and Heart Failure.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrew Eisen Research Topics

Disease

6	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 02/2022 - 08/2006
2	Dementia (Dementias) 01/2021 - 05/2007
2	2 Gingival Fibromatosis 01/2018 - 10/2017
2	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2017 - 03/2011
2	Heart Failure 10/2017 - 12/2016
2	Fasciculation (Fasciculations) 09/2013 - 03/2008
2	Insulin Resistance 05/2007 - 05/2005
1	Multiple Sclerosis 04/2022
1	Neuroinflammatory Diseases 01/2021
1	Neoplasms (Cancer) 11/2020
1	Triple Negative Breast Neoplasms 11/2020
1	Muscular Atrophy (Muscle Atrophy) 01/2020
1	Wounds and Injuries (Trauma) 01/2020
1	Melanoma (Melanoma, Malignant) 01/2018
1	Acute-Phase Reaction 01/2018
1	Papillary Thyroid Cancer 01/2018
1	Hypoglycemia (Reactive Hypoglycemia) 10/2017
1	Spinal Cord Injuries (Spinal Cord Injury) 01/2017
1	Headache (Headaches) 12/2016
1	Left Ventricular Dysfunction 12/2016
1	Nausea 12/2016
1	Pathologic Processes 11/2016
1	Death (Near-Death Experience) 11/2013
1	Sarcoma (Soft Tissue Sarcoma) 07/2011
1	Type 2 Diabetes Mellitus (MODY) 05/2007
1	Prediabetic State (Prediabetes) 05/2007

Drug/Important Bio-Agent (IBA)

3	cimaglerminIBA 01/2018 - 12/2016
2	PrionsIBA 11/2017 - 11/2016
2	Glucose (Dextrose)FDA LinkGeneric 10/2017 - 05/2007
2	Biomarkers (Surrogate Marker)IBA 01/2017 - 09/2013
1	Immunoglobulins (Immunoglobulin)IBA 04/2022
1	RX-5902IBA 11/2020
1	Immune Checkpoint InhibitorsIBA 11/2020
1	CateninsIBA 11/2020
1	Environmental Pollutants (Pollutants, Environmental)IBA 01/2020
1	EnzymesIBA 01/2018
1	BilirubinIBA 01/2018
1	Bile Acids and Salts (Bile Acids)IBA 01/2018
1	Transaminases (Aminotransferases)IBA 01/2018
1	Taurocholic Acid (Sodium Taurocholate)IBA 01/2018
1	2,5-dichloro-4-bromophenol (B 2)IBA 01/2018
1	Blood Glucose (Blood Sugar)IBA 10/2017
1	Neuregulin-1 (Neuregulin 1)IBA 10/2017
1	MicroRNAs (MicroRNA)IBA 01/2017
1	salicylhydroxamic acid (SHAM)IBA 01/2017
1	Biological ProductsIBA 01/2017
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2016
1	RNA-Binding Protein FUSIBA 07/2011
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 05/2008
1	UbiquitinIBA 05/2007
1	Superoxide Dismutase-1IBA 08/2006
1	ResistinIBA 05/2005

Therapy/Procedure

4	Therapeutics 10/2017 - 03/2011
2	Intravenous Infusions 04/2022 - 12/2016
2	Transcranial Magnetic Stimulation 01/2021 - 10/2013
1	Respite Care 02/2022
1	Tourniquets 01/2020
1	Blood Flow Restriction Therapy 01/2020
1	Aftercare (After-Treatment) 10/2017
1	Gastrostomy 11/2013
1	Denervation 03/2008